News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
2seventy bio, Inc. - Common Stock
(NQ:
TSVT
)
4.870
+0.050 (+1.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 2seventy bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 03, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
May 02, 2023
From
2seventy bio
Via
Business Wire
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program
May 01, 2023
From
2seventy bio
Via
Business Wire
2seventy bio's Return On Capital Employed Overview
March 20, 2023
Via
Benzinga
Wedbush Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
March 17, 2023
Via
Benzinga
Where 2seventy bio Stands With Analysts
March 17, 2023
Via
Benzinga
SVB Leerink Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
January 10, 2023
Via
Benzinga
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
April 28, 2023
From
2seventy bio, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
April 24, 2023
On Monday, 147 stocks made new 52-week lows.
Via
Benzinga
Expert Ratings for 2seventy bio
January 10, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
April 21, 2023
During Friday's session, 149 stocks hit new 52-week lows.
Via
Benzinga
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit
April 19, 2023
The company could have the best-in-class CAR-T drug for multiple myeloma patients.
Via
Investor's Business Daily
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
April 17, 2023
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
March 16, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
March 08, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
March 03, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
February 28, 2023
From
2seventy bio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 28, 2023
Via
Benzinga
2seventy bio Announces Proposed Public Offering of Common Stock
February 28, 2023
From
2seventy bio, Inc.
Via
Business Wire
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
February 10, 2023
Via
Benzinga
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
February 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
February 01, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Provides Company Outlook for 2023
January 09, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
January 06, 2023
From
2seventy bio, Inc.
Via
Business Wire
4 Analysts Have This to Say About 2seventy bio
November 08, 2022
Over the past 3 months, 4 analysts have published their opinion on 2seventy bio (NASDAQ:TSVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
November 07, 2022
From
2seventy bio, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
December 22, 2022
Thursday's session saw 329 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
December 20, 2022
On Tuesday, 298 companies achieved new lows for the year.
Via
Benzinga
2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
November 03, 2022
From
2seventy bio, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Upgrades
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.